Arthritis & Rheumatism
FDA expands pediatric indication for Rinvoq
The U.S. Food and Drug Administration has expanded indications for AbbVie's Rinvoq (upadacitinib) to now include pediatric patients (ages 2 years and older) with polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic ...
Jun 24, 2024
0
0
